Insmed Incorporated
insmed.comWhat Do They Do?
Sells ARIKAYCE, an inhaled medicine for Mycobacterium avium complex lung disease, and BRINSUPRI, an oral medicine for bronchiectasis, through specialty pharmacies and a specialty distributor.
10-K for FY2025, filed Feb 19, 2026Our two commercial products, ARIKAYCE® and BRINSUPRI®, are both part of the Respiratory therapeutic area. ARIKAYCE is approved in the US as…View ↗
BRINSUPRI (brensocatib 25 mg and 10 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (referred to as…View ↗
Product revenues, net consist of global net sales of ARIKAYCE and US net sales of BRINSUPRI. The Company's customers in the US include…View ↗
How Do They Make Money?
Insmed sells ARIKAYCE globally and BRINSUPRI in the U.S. to specialty pharmacies and a specialty distributor; it counts each product sale when the customer receives the medicine.
10-K for FY2025, filed Feb 19, 2026Product revenues, net consist of global net sales of ARIKAYCE and US net sales of BRINSUPRI. The Company's customers in the US include…View ↗
Product revenues, net, consist of net sales of ARIKAYCE and BRINSUPRI. We recognize revenue for product received by our customers net of…View ↗
In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of…View ↗
-
10-K for FY2025, filed Feb 19, 2026
FY2025 revenue by product or service ↗
$606.4M
-
10-K for FY2025, filed Feb 19, 2026
$606.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
ARIKAYCE
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
72% |
ARIKAYCE, FY2025
$433.8M Sources
|
Sold outright |
|
BRINSUPRI
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
28% |
BRINSUPRI, FY2025
$172.7M Sources
|
Sold outright |
Who Are Their Customers?
In the U.S., Insmed sells to specialty pharmacies and a specialty distributor; ARIKAYCE is sold globally, while BRINSUPRI sales are in the U.S.
10-K for FY2025, filed Feb 19, 2026
Do Revenues Turn Into Profits?
No. It lost $1.3B in FY2025.
10-K for FY2025, filed Feb 19, 2026
−$1.2BView ↗
10-K for FY2025, filed Feb 19, 2026
−$1.3BView ↗
10-K for FY2025, filed Feb 19, 2026
−$967.6MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$13.2MView ↗
- ▼ −96% (Loss)
- vs −$321.7M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 6, 2026
Open tableView ↗
-
Aug 6, 2026
Raises BRINSUPRI revenue guidance
Raised 2026 BRINSUPRI revenue guidance to $1.25 billion to $1.40 billion and reiterated ARIKAYCE guidance of $450 million to $470 million.
Sources
8-K, filed Aug 6, 2026
The Company raised its guidance for full-year 2026 BRINSUPRI revenues to a range of $1.25 billion to $1.40 billion from the previous…View ↗
Growing. Revenue grew 3.2x in 4 years, from $188.5M in FY2021 to $606.4M in FY2025, about 34% a year.
A second marketed lung medicine
The older report presents ARIKAYCE as a commercial product and brensocatib as a clinical-stage candidate for bronchiectasis; the latest report lists BRINSUPRI as a commercial treatment for bronchiectasis.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 19, 2026
Loading...
